National Institutes of Health logo

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

National Institutes of Health

Federal

Funding Amount

Not stated

Deadline

January 7, 2027

95 days left

Grant Type

Federal

Can we apply?

Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.

Eligible organizations

  • Nonprofits without 501(c)(3) status
  • County governments
  • Small businesses
  • School districts
  • Public colleges & universities
  • State governments
  • Nonprofits (501(c)(3))
  • Public & Indian housing authorities

Other requirements

  • Territory or Possession.

Overview

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

Details

  • Agency: National Institutes of Health
  • Department: Department of Health and Human Services
  • Opportunity #: PAR-25-070
  • Instrument: grant

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Related Grants

Open grants from this funder and similar programs

Your AI grants department

Ready to apply for Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)?

Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.

You found Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed). Now let's win it.

Start writing